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Abstract
Hexabromocyclododecane (HBCD) and tetrabromobisphenol A (TBBPA) are flame retardants, 
used in a variety of applications, which contaminate the environment and are found in human 
blood. HBCD and TBBPA have been shown to alter the tumor killing function of natural killer 
(NK) lymphocytes and the secretion of the inflammatory cytokines interferon gamma (IFNγ) and 
interleukin 1 beta (IL-1β). The current study examined the effects of HBCD and TBBPA on 
secretion of the critical pro-inflammatory cytokine tumor necrosis factor alpha (TNFα) from 
human immune cells. Preparations of human immune cells that ranged in complexity were studied 
to determine if the effects of the compounds were consistent as the composition of the cell 
preparation became more heterogeneous. Cell preparations studied were: NK cells, monocyte-
depleted (MD) peripheral blood mononuclear cells (PBMCs), and PBMCs. Exposure of NK cells 
to higher concentrations of HBCD (5 and 2.5 μM) caused decreased secretion of TNFα. However, 
when the cell preparation contained T lymphocytes (MD-PBMCs and PBMCs) these same 
concentrations of HBCD increased TNFα secretion as did nearly all other concentrations. This 
suggests that HBCD’s ability to increase TNFα secretion from immune cells was dependent on the 
presence of T lymphocytes. In contrast, exposures to TBBPA decreased the secretion of TNFα 
from all immune cell preparations regardless of the composition of the cell preparation. Further, 
HBCD-induced increases in TNFα secretion utilized the p38 MARK pathway. Thus, both HBCD 
and TBBPA may have the capacity to disrupt the inflammatory response with HBCD having the 
potential to cause chronic inflammation.
Keywords
NK cells; PBMCs; Granulocytes; hexabromocyclododecane; tetrabromobisphenol A; TNFα
INTRODUCTION
Pro-inflammatory cytokines such as Tumor necrosis factor alpha (TNFα) are crucial in the 
immune response to invading pathogens. If levels of this key regulator of the inflammatory 
response are too low, an inadequate immune response occurs. Conversely, if levels of TNFα 
are elevated in the absence of infection then chronic inflammation can develop (Guicciardi 
and Gores 2009; Khalil et al., 2006; Silke 2011; Goetz et al., 2004). TNFα is produced 
predominantly by lymphocytes and monocytes/macrophages (Khalil et al., 2006). TNFα 
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exists in soluble and membrane-bound forms. The soluble form is produced by the 
metalloprotease TNFα-converting-enzyme (TACE) cleavage of membrane TNF (Khalil et 
al., 2006). The signaling pathways that regulate TNFα production include nuclear factor 
kappa B (NFκB), and mitogen activated protein kinase (MAPK) (ERK 1/2, p38, and JNK) 
pathways (Gaestel et al., 2009). TNFα has the capacity to increase the proliferation and 
invasiveness of tumor cells (Vajdic, 2009). Due to its capacity to cause chronic 
inflammation, TNFα has been linked to the development of a number of diseases including 
Crohn’s diseases and certain cancers (Chowers and Allez, 2010; Macarthur et al., 2004; 
Balkwill and Mantovani, 2001).
Flame retardants are used in the manufacture of plastics, textiles, upholstery and electronic 
products (Birnbaum and Staskal, 2004). Halogenated hydrocarbons are the most commonly 
used flame retardants in industry (Birnbaum and Staskal, 2004). Hexabromocyclododecane 
(HBCD) is a non-aromatic, brominated cyclic alkane which is primarily used as an additive 
flame retardant (Schecter et al., 2012). It is used in foam and expanded polystyrene 
insulation (Birnbaum and Staskal, 2004). Additionally, HBCD is applied to upholstery 
textiles used in furniture, drapery and wall coverings (Kajiwara et al., 2009). Since HBCD is 
not chemically bound to plastics or textiles, it can separate and leach from the surface of 
these products into the environment (de Wit, 2002). Due to its hydrophobic nature, it binds 
to soil, sediments and sewage sludge and is found in dust particles in the air (Hale et al., 
2006; Abdallah et al., 2008; Remberger et al., 2004). Human exposure to HBCD occurs 
through dust ingestion and dietary exposure (Abdallah et al., 2008; Knutsen et al., 2008; van 
Leeuwen et al., 2008). Significant concentrations of (0.01–1.36 ng/g w/w) HBCD have been 
found in food products including beef, fish, peanut butter, pork, and turkey collected from 
grocery stores (Schecter et al., 2012). Studies have reported moderate concentrations of 
HBCD in human blood, adipose tissue, and breast milk (Knutsen et al., 2008; Pulkrabora et 
al., 2009; Kakimoto et al., 2008). Levels in human blood serum of 100 pg/g serum 
(approximately 0.16 nM, using a conversion factor of 400 mg lipid/100 mL serum) have 
been found (Covaci et al., 2006; Knutsen et al., 2008). Van der Ven et al. (2006) reported an 
increase in liver and pituitary weight and levels of cholesterol in rats exposed to HBCD. 
Tetraboromobisphenol A (TBBPA) is mainly used as a reactive flame retardant in epoxy 
resin circuit boards (IPCS/WHO, 1995). TBBPA enters the environment from treated 
products (Sellström and Jansson, 1995). It has been found in commercial drinking water 
stored in polycarbonate containers (Peterman et al. 2000). Studies in Japan and Norway have 
shown TBBPA in human serum samples (approximately 1.8–5.3 pM), averaging 4.5 ng/g 
lipid (approximately 33.8 pM) respectively (Nagayama et al., 2001; Thomsen et al., 2002). 
In mice, it has been shown to cause decreases in serum proteins and red blood cells as well 
as increases in spleen weight (Ronisz et al., 2004).
Previous studies showed that exposures to both HBCD and TBBPA decreased the ability of 
human NK cells to destroy tumor target cells (Hinkson and Whalen 2009; Kibakaya et al., 
2009) while decreasing expression of several key cell-surface proteins needed for NK cells 
to bind to target cells (Hinkson and Whalen, 2010; Hurd and Whalen, 2011). Other studies 
showed that exposing immune cells to HBCD and TBBPA altered the secretion of the 
inflammatory cytokines interferon gamma (IFNγ) and interleukin 1β (IL-1β) (Almughamsi 
and Whalen, 2015; Anisuzzaman and Whalen, 2016). As mentioned earlier, chronic 
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inflammation associated with elevated levels of TNFα has been associated with diseases 
such as Crohn’s disease and certain cancers (Chowers and Allez, 2010; Macarthur et al., 
2004; Balkwill and Mantovani, 2001); therefore it is important to study if exposure to 
HBCD or TBBPA, would affect the secretion of TNFα.
The current study examines the effects of exposures to a range of HBCD and TBBPA 
concentrations on secretion of TNFα from preparations of human immune cells of varying 
complexity: NK cells, monocyte-depleted (MD)-peripheral blood mononuclear cells 
(PBMCs) (T and NK lymphocytes), and PBMCs (monocytes and lymphocytes). This 
allowed us to determine if the effects of the compounds were altered as the composition of 
the cell preparation became more heterogeneous. Additionally, the signaling pathways 
involved in compound-induced increases in TNFα secretion were examined using selective 
inhibitors of pathways known to be involved in the secretion of TNFα (Gaestel et al., 2009).
MATERIALS AND METHODS
Preparation of PBMCs, and monocyte-depleted PBMCS
PBMCs were isolated from Leukocyte filters (PALL-RCPL or RC2D) obtained from the Red 
Cross Blood Bank Facility (Nashville, TN) as described in Meyer et al., 2005. Leukocytes 
were retrieved from the filters by back-flushing them with an elution medium (sterile PBS 
containing 5 mM disodium EDTA and 2.5% [w/v] sucrose) and collecting the eluent. The 
eluent was layered onto Ficoll-Hypaque (1.077g/mL) and centrifuged at 1200g for 30 min. 
Granulocytes and red cells pelleted at the bottom of the tube while the PBMCs floated on 
the
Ficoll-Hypaque. Mononuclear cells were collected and washed with PBS (500g, 10min). 
Following washing, the cells were layered on bovine calf serum for platelet removal. The 
cells were then suspended in RPMI-1640 complete medium which consisted of RPMI-1640 
supplemented with 10% heat-inactivated BCS, 2 mML-glutamine and 50 U penicillin G with 
50 μg streptomycin/mL. This preparation constituted PBMCs. Monocyte-depleted PBMCs 
(10–20% CD16+, 10–20 % CD56+, 70–80% CD3+, 3–5% CD19+, 2–20% CD14+) were 
prepared by incubating the cells in glass Petri dishes (150 in diameter) at 37 °C and air/CO2, 
19:1 for 1 h. This cell preparation is referred to as MD-PBMCs cells.
Preparation of NK cells
Leukocytes were retrieved from the filters by back-flushing them with an elution medium 
(sterile PBS containing 5 mM disodium EDTA and 2.5% [w/v] sucrose) and collecting the 
eluent as described above. RosetteSep human NK cell enrichment antibody cocktail (0.6–0.8 
mL) (StemCell Technologies, Vancouver, British Columbia, Canada) was added to 45 mL of 
filter eluent. The mixture was incubated for 25 min at room temperature (~ 25º C). 
Approximately 8 mL of the mixture was layered onto 4 mL of Ficoll-Hypaque (1.077 g/mL) 
(MP Biomedicals, Irvine, CA) and centrifuged at 1200 g for 30 min. NK cells were collected 
and washed twice with phosphate buffered saline (PBS) pH 7.2 and stored in complete 
media (RPMI-1640 supplemented with 10% heat-inactivated bovine calf serum (BCS), 2 
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mM L-glutamine and 50 U penicillin G with 50 μg streptomycin/ml) at 1 million cells/mL at 
37 °C and air/CO2, 19:1.
Chemical Preparation
HBCD and TBBPA were purchased from Sigma-Aldrich (St. Louis, MO). Stock solutions 
were prepared as 100 mM solutions in Dimethylsulfoxide (DMSO). Desired concentrations 
of either HBCD or TBBPA were prepared by dilution of the stock into media.
Inhibitor Preparation
Enzyme inhibitors were purchased from Fischer Scientific (Pittsburgh, PA). Each inhibitor 
was prepared as a 50 mM stock solution in DMSO. JNK inhibitor (JNK X BI78D3) at a final 
concentration of 50 μM, MEK 1/2 pathway inhibitor (PD98059) at a final concentration of 
50 μM, NFκB inhibitor (BAY11-7085) at a final concentration of 1.25–0.3 μM, p38 inhibitor 
(SB202190) at a final concentration of 25 μM, and TACE inhibitor (Batimastat) at a final 
concentration of 25 μM were prepared by appropriate dilution of the stock solution into cell 
culture media.
Cell Treatments
NK cells, MD-PBMCS, and PBMCs were treated with HBCD or TBBPA at concentrations 
of 0.05–5 μM for 24 h, 48 h, or 6 days. Following the incubations, the cells were pelleted 
and supernatants were collected and stored at −70° C until assaying for TNFα.
For pathway inhibitor experiments, MD-PBMCs (at a concentration of 1.5 million cells/mL) 
were treated with enzyme inhibitors 1h before adding HBCD at concentrations of 2.5, 1, 0.5 
μM for 24 h. Following the incubations, the cells were pelleted and supernatants were 
collected and stored at −70° C until assaying for TNFα.
Cell Viability
Cell viability was assessed at the end of each exposure period. Viability was determined 
using the trypan blue exclusion method. Briefly, cells were mixed with trypan blue and 
counted using a hemocytometer. The total number of cells and the total number of live cells 
were determined for both control and treated cells to determine the percent viable cells. 
Exposure to the compounds caused no changes in viability of any of the cell preparations 
compared to that of the control (data not shown).
TNFα Secretion Assay
TNFα levels were measured using the BD OptEIATM Human TNFα enzyme-linked 
immunosorbent assay (ELISA) kit (BD-Pharmingen, San Diego, CA). Briefly, a 96-well 
micro well plate, designed for ELISA (Fisher, Pittsburgh, PA), was coated with a capture 
antibody for TNFα diluted in coating buffer. The plate was incubated with the capture 
antibody overnight at 4° C. After incubation, the capture antibody was removed by washing 
the plate three times with wash buffer (PBS and 0.05% Tween-20). Assay diluent (PBS and 
bovine calf serum) was added to each well (blocking non-specific binding) and incubated at 
room temperature for 1h. The assay diluent was removed by washing the plate three times, 
and the cell supernatants and TNFα standards were added to the coated plated and incubated 
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for 2h at room temperature. Following this incubation, the plate was thoroughly washed five 
times and then incubated for 1h with a detection antibody linked to horseradish peroxidase 
(HRP). The detection antibody-HRP complex was removed by washing the plate seven times 
and then the plate was incubated for 30 min with substrates for horseradish peroxidase. The 
incubation with the substrates was ended by addition of acid and the absorbance was 
measured at 450 nm on a Thermo Labsystems Multiskan MCC/340 plate reader (Fisher 
Scientific).
Statistical Analysis
Statistical analysis of the data was performed by using ANOVA and Student’s t test. Data 
were initially compared within a given experimental setup by ANOVA. A significant 
ANOVA was followed by pair wise analysis of control versus exposed data using Student’s t 
test, a p-value of less than 0.05 was considered significant.
RESULTS
Effects of HBCD Exposure on Secretion of TNFα by NK cells
Table 1 shows the effects of exposing NK cells from 4 separate donors to 0, 0.05, 0.1, 0.25, 
0.5, 1, 2.5, 5 μM HBCD for 24 h, 48 h and 6 days on TNFα secretion (KB = Key Biologic 
buffy coat; F = filter obtained from the Red Cross). Cells from all 4 donors showed a 
significant decrease in TNFα secretion when exposed to 5 μM HBCD after 24 h, and at 2.5 
and 5 μM after 48 h and 6 days. Additionally, all donors demonstrated increased TNFα 
secretion in response to HBCD. However, these increases were usually quite small and the 
concentrations and lengths of exposure where they occurred varied from one donor to the 
next. For instance, cells from donor F429 showed the greatest HBCD-induced increase (3.6 
fold) after 6 days of exposure at the 1 μM exposure, while cells from donor F430 showed a 
maximum HBCD-stimulated increase of only 1.14 fold after 48 h. In contrast, the decreases 
in TNFα secretion seen with 2.5 and 5 μM HBCD were very substantial. Figure 1A shows 
the effects of HBCD exposures at each of the lengths of exposure for an individual donor 
(F429).
Effects of HBCD Exposure on Secretion of TNFα by MD-PBMCs
The effects of exposing MD-PBMCs from 4 individual donors to 0 to5 μM HBCD for 24 h, 
48 h and 6 days on the secretion of TNFα are shown in Table 2. This preparation is mostly 
NK cells and T cells. In stark contrast to the effects of HBCD on NK cells, there were 
significant increases in TNFα secretion from MD-PBMC from all donors examined after all 
lengths of exposure to HBCD. Significant increases in TNFα secretion were induced by 
HBCD for all donors at the 0.1, 0.25, 0.5, 1, 2.5, and 5 μM concentrations after 24 h and/or 
48 h of exposure. There was considerable variation in the fold increase in secreted TNFα 
among different donors. For example, cells from donor F283 treated with 2.5 μM HBCD 
showed an increase of 1.7 fold after 24 h while cells from donor F291 exhibited and increase 
7.9 fold after this same treatment. The results after a 6 day exposure to HBCD were similar 
to those seen after 24 and 48 h exposures. Figure 1B shows the effects of HBCD exposures 
at each of the lengths of exposure for an individual donor (F284).
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Effects of HBCD Exposure on Secretion of TNFα by PBMCs
The effects of exposures to HBCD on TNFα secretion from PBMCs (a preparation 
including NK cells, T cells, and monocytes) are shown in Table 3 and are very similar to 
those seen with MD-PBMCs. Cells from all donors showed increased TNFα secretion in 
response to 2.5 and/or 5 μM HBCD after the 24 h and 48 h exposures. As with MD-PBMCs, 
the magnitude of the increases seen at a given HBCD concentration varied from one donor 
to the next. For instance, the fold increases in TNFα secretion seen with a 24 h exposure to 5 
μM HBCD were 2.5 (F189), 1.4 (F192), 2.0 (F195), and 18 (F356). Figure 1C shows the 
effects of HBCD exposures at each of the lengths of exposure for an individual donor 
(F195).
Effects of TBBPA Exposure on Secretion of TNFα by NK cells
Table 4 summarizes the effects of exposing NK cells to 0, 0.05, 0.1, 0.25, 0.5, 1, 2.5, and 5 
μM TBBPA for 24 h, 48 h and 6 days on the secretion of TNFα. Cells prepared from 4 
separate donors were tested. Overall results show that TNFα secretion decreased as the 
concentration of TBBPA increased. This pattern of decreases was seen in all donors over all 
lengths of incubation. Figure 2A shows the effects of TBBPA exposures at each of the 
lengths of exposure for an individual donor (KB386).
Effects of TBBPA Exposure on Secretion of TNFα by MD-PBMCs
As was seen with NK cells, MD-PBMCs exposed to 0–5 μM TBBPA also showed decreased 
secretion of TNFα in response to exposure. MD-PBMCs (predominantly T and NK 
lymphocytes) from all donors showed very significant decreases in TNFα secretion at 2 or 
more TBBPA exposure concentrations after 24 h and 48 h (Table 5). A similar trend was 
seen at 6 days. Figure 2B shows the effects of TBBPA exposures at each of the lengths of 
exposure for MD-PBMCs from individual donor (F284).
Effects of TBBPA Exposure on Secretion of TNFα by PBMCs
The effects of exposing PBMCs (lymphocytes +monocytes) to TBBPA were similar to those 
seen with NK cells and MD-PBMCs (Table 6). Cells from all donors showed TBBPA-
induced decreases in TNFα secretion at the 1, 2.5 and/or 5 μM concentrations after 24 h and 
48 h. This pattern persisted out of 6 days of exposure. Figure 2C shows the effects of 
TBBPA exposures at each of the lengths of exposure for an individual donor (F381).
Effects of HBCD Exposure on Secretion of TNFα by MD-PBMCs with Selective Enzyme 
Inhibitors
JNK Inhibitor (JNK Inhibitor X BI78D3)—The effects of exposure to 0.5, 1, and 2.5 μM 
HBCD on secretion of TNFα from MD-PBMCs where JNK had been inhibited with 
B178D3 are shown in Table 7. These results indicate that JNK is not needed for HBCD-
induced increases in TNFα secretion. For example, in Figure 3A, there are 1.9, 2.1, and 7.8 
fold increases when MD-PBMCs (donor F412) are exposed to 0.5, 1 and 2.5 μM HBCD in 
the absence of JNK inhibitor. When the inhibitor is present those same HBCD exposures are 
able to cause 2.3, 2.7, 7.9 fold increases in TNFα secretion.
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MEK Inhibitor (PD98059)—The results of experiments examining the ability of 0.5, 1, 
and 2.5 μM HBCD to stimulate TNFα secretion from MD-PBMCs where the ERK 1/2 
pathway has been inhibited with the MEK inhibitor PD98059 are shown in Table 7. 
PD98059 did not tend to diminish the ability of HBCD to increase TNFα release from MD-
PBMCs. For example, MD-PBMCs from donor F421exposed to 0.5, 1 and 2,5 μM HBCD 
showed increases in TNFα secretion of 2.3, 4.6, and 6.1 fold, respectively in the absence of 
PD98059. In the presence of the inhibitor, these same HBCD concentration caused increased 
secretion of TNFα of 2.6, 6.4, and 11 fold (Figure 3B). Thus, the ERK1/2 pathway does not 
appear to be essential for HBCD-induced increases in TNFα secretion.
NFκB Inhibitor (BAY 11-7085)—Cells from 4 of the 5 donors tested showed diminished 
HBCD-induced secretion of TNFα when the NFκB pathway was inhibited (Table 7) at a 
minimum of one exposure concentration. Figure 3C shows the data from donor F412 where 
the increases in TNFα secretion in response to 005, 1, and 2.5 μM HBCD were 1.6, 2.2, and 
8.9 when BAY 11-7085 was absent, those same HBCD concentrations caused increases of 
1.9, 2.1, and 6.4 when the inhibitor was present. These data suggest that the NFκB pathway 
may contribute to the HBCD induction of TNFα secretion, but that it is not the principle 
pathway being utilized by HBCD to increase TNFα secretion.
p38 Inhibitor (SB202190)—HBCD-induced increases in TNFα were diminished or 
blocked at one or more concentration in cells from all donors (Table 7). Figure 3D shows 
that cells from donor F412 had increases of 1.3, 1.6, and 4.1 fold in the secretion of TNFα 
after exposure to 0.5, 1, and 2.5 μM HBCD. These increases in TNFα secretion were 
completely blocked in the presence of SB202190. These results indicated that the p38 
pathway may play a role in HBCD-induced stimulation of TNFα from immune cells.
TACE and MMP Inhibitor (Batimastat)—The effects of exposure to 0.5, 1, and 2.5 μM 
HBCD on secretion of TNFα from MD-PBMCs where TACE had been inhibited with 
Batimastat are shown in Table 7. MD-PBMCs from donor F417 showed 1.9, 1.5, and 5.5 
fold increases in TNFα secretion when exposed to 0.5, 1 and 2.5 μM HBCD in the absence 
of TACE inhibitor (Figure 4E). When the inhibitor was present those same HBCD exposures 
were able to cause 3.4, 2.6, and 3.5 fold increases in TNFα secretion. Although inhibition of 
TACE decreases baseline secretion of TNFα dramatically, HBCD was still able to cause 
similar fold increases in TNFα secretion except at the 2.5 μM exposure. There was at least 
one concentration of HBCD where inhibition of TACE did result in decreased HBCD-
induced TNFα secretion from cells from each donor (Table 7). These results indicate that 
HBCD may be utilizing the pathway associated with the TACE and MMP to cause the 
secretion of TNFα in a concentration dependent manner.
DISCUSSION
TNFα is considered a master regulator of inflammatory cytokine production (Parameswaran 
and Patial, 2010). Dysregulation of TNFα has been associated with rheumatoid arthritis, 
Crohn’s disease, and cancers such as gastrointestinal cancer. (Macarthur et al., 2004 and 
Shurety et al., 2000). Flame retardants, HBCD and TBBPA, are used in manufacturing 
goods such as plastics, textiles, and electronic products (Birnbaum and Staskal, 2004). Both 
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are found in human blood (Germer et al., 2006; Covaci et al., 2006; Knutsen et al., 2008; 
Van der Ven et al., 2006; Nagayama et al., 2001; Thomsen et al., 2002). Previous studies 
showed that exposing immune cells to HBCD and TBBPA altered the secretion of the 
inflammatory cytokines interferon gamma (IFNγ) and interleukin 1β (IL-1β) (Almughamsi 
and Whalen, 2015; Anisuzzaman and Whalen, 2016). The current study shows the effects of 
these contaminants on the ability of human immune cells to secrete TNFα.
Exposure of MD-PBMCs and PBMCs to HBCD caused increased TNFα secretion. Unlike 
MD-PBMCs and PBMCs, NK cells exposed to HBCD showed decreased secretion of TNFα 
at the 2 highest concentrations, 2.5 and 5 μM. NK cells from all donors also showed HBCD-
induced increases in TNFα release but only at a few concentrations of HBCD and the time 
that it took to see these increases varied among cells from different donors. For example, NK 
cells from two donors showed increases at only 2 concentrations of HBCD after 24 h of 
exposure. In contrast, MD-PBMCs from all donors showed increased TNFα secretion at 
nearly all HBCD concentrations after a 24 h exposure. Thus, there appears to be a difference 
in effect of HBCD on TNFα secretion depending on the composition of the cell preparation. 
Those preparations containing T and NK lymphocytes (MD-PBMCs) and lymphocytes and 
monocytes (PBMCs) showed a markedly different patterns of response to the same HBCD 
exposures than did a preparation that was predominantly NK lymphocytes. The more 
complex preparations (MD-PBMCs and PBMCs) may be more reflective of the situation in 
vivo and thus, HBCD-induced stimulation of TNFα secretion might be more likely than the 
decreases. Interestingly, this distinction between the least complex preparation (NK cells) 
and the more complex, MD-PBMCs and PBMCs, was not seen when measuring the effects 
of HBCD on IFNγ or IL-1β secretion (Almughamsi and Whalen, 2015; Anisuzzaman and 
Whalen, 2016) but was seen when examining the effects of organotin contaminants, 
tributyltin and dibutyltin, on TNFα secretion (Hurt et al., 2013). This suggests that the 
regulation of secretion and/or production of TNFα from NK cells may be different than that 
of T cells and/or monocytes (Stanley and Lacy, 2010; Gaestel et al., 2009).
When immune cells were exposed to TBBPA, secretion of TNFα was significantly 
decreased at the highest concentrations in cells from all donors at all lengths of exposure 
regardless of the complexity of the cell preparation. Unlike HBCD, each of the different cell 
preparations showed similar responses to TBBPA in terms of TNFα secretion. Previous 
studies examining the effects of TBBPA on secretion of IFNγ and IL-1β from human 
immune cells also showed decreased TNFα secretion in response to TBBPA exposures 
(Almughamsi and Whalen, 2015; Anisuzzaman and Whalen, 2016).
After establishing that HBCD-induced increases in TNFα release were occurring, inhibitors 
of pathways utilized in the production/secretion of TNFα were examined for their ability to 
alter this effect. Mitogen-activated protein kinase (MAPK) pathways including JNK, p38 
and ERK1/2 as well as the nuclear factor kappa B (NFκB) pathway and the metalloprotease 
TNFα converting enzyme (TACE) TACE are known to regulate the secretion/production of 
TNFα (Gaestel et al., 2009; Khalil et al., 2006; Wajant, 2003). MD-PBMCs were chosen for 
the pathway studies due to their consistent HBCD-induced increases in the secretion of 
TNFα after a 24 h exposure. The JNK and ERK1/2 MAPK pathways were not essential to 
the HBCD-induced increases in TNFα secretion. TACE activity appeared to be needed for 
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HBCD to stimulate increased secretion of TNFα, but only at certain concentrations of 
HBCD (which varied from donor to donor). The NFκB pathway appears to contribute to 
HBCD stimulation of the secretion of TNFα, but blocking its function only somewhat 
inhibits the process. In contrast to the other pathways, the p38 MAPK pathway appears to be 
consistently utilized by HBCD in its stimulation of TNFα secretion. Previous studies 
examining the role of MAPK and NFκB pathways on HBCD-induced increases in IFNγ and 
IL-1β indicated that the ERK1/2 pathway was needed for HBCD-induced secretion of IFNγ 
(Almughamsi and Whalen, 2015) and that both the p38 and ERK1/2 pathways were utilized 
when HBCD increased the secretion of IL-1β (Anizussaman and Whalen, 2015).
TNFα has the capacity to cause chronic inflammation, which may lead to diseases such as 
rheumatoid arthritis, Crohn’s disease, and cancers (Macarthur et al., 2004; Shurety et al., 
2000). Studies suggest that TNFα inhibitors may provide a first-line biologic therapy in 
managing rheumatoid arthritis and Crohn’s disease; these studies showed successful 
treatment of rheumatoid arthritis and Crohn’s disease when treated with anti-TNFα antibody 
(Barnabe et al., 2011; Khalil et al., 2006; Michaud et al., 2014).
The current study indicates that flame retardants, HBCD and TBBPA, alter secretion of 
TNFα from human immune cells. Both flame retardants have the ability to disrupt TNFα 
release from increasingly complex human immune cells preparations. HBCD increased 
TNFα secretion from MD-PBMCs (T cells + NK cells) and PBMCs (T cells + NK cells + 
monocytes). As mentioned above, HBCD-induced stimulation of TNFα secretion might be 
more likely than the decreases since the more complex preparations (MD-PBMCs and 
PBMCs) may be more reflective of the situation in vivo. In contrast, TBBPA decreased 
secretion of TNFα in all cell preparations. Further studies with selective enzyme inhibitors 
suggested that HBCD is utilizing the p38 MAPK pathway to produce a pro-inflammatory 
signal. As mentioned in the introduction, p38 is a pathway that leads to transcription of the 
TNFα gene (Gaestel et al., 2009). Thus, TBBPA may have the capacity to cause inadequate 
immune responsiveness by decreasing the ability of immune cells to secrete TNFα while 
HBCD may contribute to chronic inflammation by increasing TNFα secretion, which may 
lead to several diseases and increased tumor invasiveness.
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Effects of 24 h, 48 h and 6 days exposures to HBCD on TNFα secretion from highly 
purified human NK cells, monocyte-depleted PBMCs, and PBMCs. A) NK cells exposed to 
0.05–5μM HBCD (donor F429). B) Monocyte-depleted PBMCs exposed to 0.05–5μM 
HBCD (donor F284). C) PBMCs exposed to 0.05–5μM HBCD (donor F195). (+) indicates a 
significant increase compared to control and (*) indicates a significant decrease compared to 
control.
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Effects of 24 h, 48 h and 6 days exposures to TBBPA on TNFα secretion from highly 
purified human NK cells, monocyte-depleted PBMCs, and PBMCs. A) NK cells exposed to 
0.05–5μM TBBPA (donor KB386). B) Monocyte-depleted PBMCs exposed to 0.05–5μM 
TBBPA (donor F284). C) PBMCs exposed to 0.05–5μM TBBPA (donor 381). (*) indicates a 
significant decrease compared to control.
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Effects of 24 h exposure to 0.5, 1, and 2.5 μM HBCD on TNFα secretion from monocyte-
depleted PBMCs with selective enzyme inhibitors in an individual donor. A) JNK inhibitor 
(donor F421). B) MEK 1/2 Inhibitor (PD98059) (donor F421). C) NFκB Inhibitor (BAY 
11-7085) (donor F412). D) p38 Inhibitor (SB202190) (donor F412). E) TACE and MMP 
Inhibitor (Batimastat) (donor F412).
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Table 1
Effects of 24 h, 48 h, and 6 days exposures to HBCD on TNFα secretion from highly purified human NKs.
24 h TNFα secretion in pg/mL (mean±S.D.)
[HBCD] μM KB-182 F410 F429 F430
0 1207±93 2669±54 202±6 81±11
0.05 1289±93 2494±55* 314±2# 99±3
0.1 1218±166 2586±130 275±59 80±5
0.25 1324±68 2775±93 238±21 94±5
0.5 1315±116 2989±125# 262±6# 90±8
1 1249±130 3047±97# 239±36 51±6*
2.5 1115±56 400±38* 59±7* 18±1*
5 736±18* 139±17* 16±1* 18±6*
48 h TNFα secretion in pg/mL (mean±S.D.)
[HBCD] μM KB-182 F410 F429 F430
0 1017±12 826±232 195±43 244±3
0.05 1112±94 1102±57 290±47 275±4#
0.1 1019±27 1095±33 280±26 191±3*
0.25 1005±12 1187±42 295±24# 268±5#
0.5 1086±32# 1052±40 260±41 287±16#
1 1113±136 1146±40 257±34 182±2*
2.5 873±24* 111±32* 21±9* 19±1*
5 482±38* 55±30* 9±6* 7±2*
6 d TNFα secretion in pg/mL (mean±S.D.)
[HBCD] μM KB-182 F410 F429 F430
0 827±64 2001±58 60±5 63±9
0.05 1354±287 1726±53* 126±19# 72±25
0.1 1230±191 1874±17 156±9# 40±3*
0.25 1264±271 2088±72 154±7# 77±7
0.5 1482±345 2202±97* 164±8# 56±1
1 1260±85# 2042±35 216±12# 39±2*
2.5 792±79 206±9* 5±3* 11±10*
5 702±33 145±58* 0±3* 8±5*
Values are mean±S.D. of triplicate determinations.
#
Indicates a significant increase and
*
indicates a significant decreases in secretion compared to control cells, p<0.05
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Table 2
Effects of 24 h, 48 h, and 6 days exposures to HBCD on TNFα secretion from monocyte-depleted PBMCs (T 
and NK Lymphocytes).
24 h TNFα secretion in pg/mL (mean±S.D.)
[HBCD]μM F283 F284 F286 F291
0 1718±162 974±29 734±25 924±41
0.05 2746±77# 975±119 950±79# 1577±51#
0.1 3599±223# 2207±99# 1294±15# 2712±15#
0.25 2128±152# 1205±130 865±16# 1410±36#
0.5 2608±94# 1756±254# 1023±21# 1690±56#
1 3592±130# 2028±109# 1518±41# 2861±64#
2.5 2907±50# 4206±435# 3882±58# 7292±282#
5 1796±121 3541±167# 4472±111# 4958±262#
48 h TNFα secretion in pg/mL (mean±S.D.)
[HBCD]μM F283 F284 F286 F291
0 684±42 327±8 201±16 98±6
0.05 1334±69# 524±57# 847±876 352±46#
0.1 2107±96# 988±21# 386±10# 1220±27#
0.25 876±67# 517±29# 399±280 236±38#
0.5 1496±121# 625±19# 366±65# 362±19#
1 2443±63# 977±30# 444±60# 1044±87#
2.5 2037±274# 3981±119# 1750±198# 6752±639#
5 1110±167# 2221±150# 1763±136# 3898±126#
6 d TNFα secretion in pg/mL (mean±S.D.)
[HBCD]μM F283 F284 F286 F291
0 81±3 51±14 0±1 81±6
0.05 496±17# 332±227 293±115# 267±110
0.1 1355±71# 374±170 71±35 841±28#
0.25 281±20# 61±10 30±30 219±45#
0.5 505±11# 107±24# 103±158 233±39#
1 1187±54# 326±19# 0±1 818±63#
2.5 1038±19# 830±34# 28±33 4009±246#
5 323±1# 297±21# 52±10# 2468±132#
Values are mean±S.D. of triplicate determinations.
#
Inidcates a significant increases and
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*
indicates a significant decrease in secretion compared to control cells, p<0.05
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Table 3
Effects of 24 h, 48 h, and 6 days exposures to HBCD on TNFα secretion from PBMCs (lymphocytes and 
monocytes).
24 h TNFα secretion in pg/mL (mean±S.D.)
[HBCD]μM F189 F192 F195 F356
0 801±16 1695±175 2074±258 358±10
0.05 1788±106# 1486±155 1172±49* 710±84#
0.1 1385±71# 1553±227 1110±91* 851±38#
0.25 2045±60# 1556±36 1679±88 423±18#
0.5 1826±106# 1870±179 1936±198 540±86
1 2491±108# 1779±107 2274±151 810±48#
2.5 3184±191# 2406±18# 3415±375# 2378±190#
5 1977±137# 2383±266# 4190±671# 6548±103#
48 h TNFα secretion in pg/mL (mean±S.D.)
[HBCD]μM F189 F192 F195 F356
0 153±14 493±87 786±176 41.2±1
0.05 264±25# 494±62 983±209 883±128#
0.1 304±20# 632±411 745±104 78±1#
0.25 528±62# 240±95* 718±111 58±4#
0.5 533±14# 567±124 1052±54 55±4#
1 581±658 802±469 1071±18 122±1#
2.5 2388±217# 898±57# 2129±144# 431±297#
5 1258±89.5# 676±8 32641±110# 1174±43#
6 d TNFα secretion in pg/mL (mean±S.D.)
[HBCD]μM F189 F192 F195 F356
0 72±21 45±68 342±16 0±2
0.05 141±115 69±20 460±62 208±260
0.1 123±41 58±8 253±23* 34±101#
0.25 385±46# 58±13 524±38# 63±11#
0.5 306±37# 75±11 456±32# 22±21
1 1596±89# 107±15 816±42# 11±11
2.5 1833±168# 142±22 1709±138# 64±19#
5 1021±17# 146±4 1880±47# 330±15#
Values are mean±S.D. of triplicate determinations.
#
Indicates a significant increase and
*
indicates a significant decrease in secretion compared to control cells, p<0.05
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Table 4
Effects of 24 h, 48 h, and 6 days exposures to TBBPA on TNFα secretion from highly purified human NKs.
24h TNFα secretion in pg/mL (mean±S.D.)
[TBBPA] μM KB-130 KB-183 F378 F386
0 486±7 40±5.7 365±13 575±34
0.05 463±20 48±13 214±4* 326±7*
0.1 405±5* 41±15 97±6* 506±18
0.25 261±5* 22±11 266±10* 196±19*
0.5 140±52* 48±8 169±3* 284±14*
1 68±7* 4±2* 70±3* 206±21*
2.5 15±2* 0±1* 19±1* 53±1*
5 0±2* 8±9* 3±2* 14±2*
48h TNFα secretion in pg/mL (mean±S.D.)
[TBBPA] μM KB-130 KB-183 F378 F386
0 342±10 233±62 267±10 382±29
0.05 350±25 206±91 126±8* 111±4*
0.1 283±14* 167±12 92±59* 51±2*
0.25 217±3* 117±6 188±4* 221±40*
0.5 95±7* 584±518 98±4* 136±3*
1 40±10* 51±46* 43±1* 54±1*
2.5 0±2* 30±32* 4±1* 7±3*
5 0±2* 18±17* 0±1* 0±3*
6d TNFα secretion in pg/mL (mean±S.D.)
[TBBPA] μM KB-130 KB-183 F378 F386
0 329±116 87±96 39±10 126±6
0.05 310±197 73±70 53±20 27±12*
0.1 250±88 48±47 34±12 8±2*
0.25 267±165 11±4 41±7 63±2*
0.5 160±186 55±38 41±5 31±7*
1 112±150 5±8 29±0 6±1*
2.5 191±311 32±25 58±7 0±1*
5 0±2* 48±50 32±9 0±2*
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant decrease in secretion compared to control cells, p<0.05
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Table 5
Effects of 24 h, 48 h, and 6 days exposures to TBBPA on TNFα secretion from monocyte-depleted PBMCs (T 
and NK Lymphocytes).
24 h TNFα secretion in pg/mL (mean±S.D.)
[TBBPA]μM F175 F284 F291 F292
0 1127±68 1255±121 484±56 1326±33
0.05 1046±59 582±173* 224±109* 293±10*
0.1 807±17* 209±34* 48±34* 164±16*
0.25 597±39* 413±39* 245±10* 615±19*
0.5 399±42* 433±171* 237±98* 297±18*
1 178±4* 161±14* 41±35* 158±10*
2.5 123±29* 232±235* 111±187 116±6*
5 157±71* 78±16* 95±55* 107±9*
48 h TNFα secretion in pg/mL (mean±S.D.)
[TBBPA]μM F175 F284 F291 F292
0 460±13 464±27 237±21 753±86
0.05 629±254 135±5* 55±11* 356±127*
0.1 302±4* 69±4* 26±9* 158±70*
0.25 369±77 243±16* 76±22* 220±9*
0.5 229±207 120±20* 70±24* 106±18*
1 147±20* 0±9* 18±5* 50±37*
2.5 193±138 0±34* 43±15* 107±19*
5 40±7* 0±9* 106±5* 138±81*
6 d TNFα secretion in pg/mL (mean±S.D.)
[TBBPA]μM F175 F284 F291 F292
0 327±15 8±1 117±92 221±9
0.05 534±308 5±1* 28±4 1435±287
0.1 234±31* 3±1* 0±10 692±185*
0.25 147±20* 4±1* 90±6 482±195*
0.5 22±44* 4±1* 12.8±3 133±50*
1 0±23* 0±1* 0±1 48±15*
2.5 0±14* 0±1* 0±4 50±13*
5 707±1361 0±1* 110±172 18±12*
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant decrease in secretion compared to control cells, p<0.05
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Table 6
Effects of 24 h, 48 h, and 6 days exposures to TBBPA on TNFα secretion from PBMCs (lymphocytes and 
monocytes).
24 h TNFα secretion in pg/mL (mean±S.D.)
[TBBPA]μM F188 F356 F381 F385
0 522±21 106±2 277±4 1384±130
0.05 614±391 199±122 110±11* 434±76*
0.1 576±346 104±37 31±8* 284±54*
0.25 292±4* 234±68 171±3* 801±289
0.5 205±3* 64±21 118±20* 934±688
1 189±7* 38±8* 39±2* 245±48*
2.5 182±3* 49±4* 62±24* 193±10*
5 197±7* 79±21 87±20* 205±36*
48 h TNFα secretion in pg/mL (mean±S.D.)
[TBBPA]μM F188 F356 F381 F385
0 87±19 14±1 91±24 216±44
0.05 161±11 8±1* 38±21* 110±30*
0.1 817±1378 6±1* 8±6* 66±26*
0.25 152±172* 9±1* 42±8 203±31
0.5 1436±2451* 5±1* 31±33 105±97
1 0±20* 5±1* 14±4* 35±18*
2.5 0±16* 7±1* 24±33 51±27*
5 0±3* 10±1* 62±9 99±59
6 d TNFα secretion in pg/mL (mean±S.D.)
[TBBPA]μM F188 F356 F381 F385
0 204±16 105±26 397±13 479±207
0.05 341±197 122±130 63±13* 114±77
0.1 132±3 134±180 22±10* 67±21
0.25 98±18* 315±460 102±8* 345±100
0.5 34±0* 48±12* 37±3* 59±31
1 8±1* 27±5* 8±3* 54±17
2.5 0±2* 50±5 20±20* 51±29
5 0±3* 6±3* 0±1* 14±2
Values are mean±S.D. of triplicate determinations.
*
Indicates a significant decrease in secretion compared to control cells, p<0.05
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